文献速递腹部MR

改良LI-RADS:靶样表现伴强化包膜可诊断为HCC而非LR-M

A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
PubMed 文献 · Eur Radiol · 2021-08-04

本研究纳入198例慢性肝病患者的258个肝结节,比较常规LI-RADS与改良LR-5C标准(靶样表现伴强化包膜归为HCC而非LR-M)在ECA-MRI和HBA-MRI上的诊断效能。改良标准在保持高特异度的同时显著提高HCC诊断敏感度,且ECA-MRI敏感度高于HBA-MRI。

要点

  • 靶样结节伴强化包膜时,按改良标准可归为HCC而非LR-M。
  • 改良标准敏感度提高而特异度保持高位,ECA-MRI敏感度更高。
  • 常规LI-RADS下部分HCC被误归为LR-M,需注意鉴别。

核心结论

  • 改良LI-RADS(mLR-5C)诊断HCC的敏感度优于常规LR-5,且特异度无显著下降。
  • 应用mLR-5C对LR-M病灶重新分类后,ECA-MRI诊断HCC的敏感度高于HBA-MRI,特异度相近。

研究设计与样本

  • 单中心回顾性研究,纳入198例慢性肝病患者(161男,平均56.3岁),共258个肝结节。
  • 所有患者术前接受ECA-MRI和HBA-MRI,由两名阅片者按LI-RADS v2018分类。
  • 参考标准为手术病理,结节包括194个HCC、43个良性病变和21个非HCC恶性肿瘤,中位大小19 mm。

关键影像表现/征象

  • 常规LI-RADS下47个(18.2%)结节归为LR-M,其中31个为HCC、16个为非HCC恶性肿瘤。
  • 31个LR-M的HCC中,应用mLR-5C后,ECA-MRI重新归类19个、HBA-MRI重新归类8个为HCC。

诊断标准与关键数值

  • mLR-5C定义:靶样表现伴强化包膜的肿瘤归为mLR-5C(HCC),而非LR-M。
  • HCC诊断敏感度:ECA-MRI 76.6% vs 67.0%(p<0.05);HBA-MRI 60.4% vs 56.3%(p<0.05),均为mLR-5C vs LR-5。
  • HCC诊断特异度:ECA-MRI 93.8% vs 98.4%(p>0.05);HBA-MRI 95.3% vs 98.4%(p>0.05),均为mLR-5C vs LR-5。
  • mLR-5C下ECA-MRI vs HBA-MRI:敏感度76.6% vs 60.4%(p<0.001),特异度93.8% vs 95.3%(p>0.99)。

临床应用与阅片要点

  • 阅片时对靶样表现结节应仔细评估是否伴强化包膜,若存在可按mLR-5C归为HCC。
  • ECA-MRI在mLR-5C标准下对HCC敏感度更高,HBA-MRI需注意假阴性可能。
  • 改良标准可能减少HCC被误归为LR-M的情况,但需结合临床和其他征象综合判断。

局限性

  • 单中心回顾性研究,样本量有限,结论需外部验证。
  • 参考标准为手术病理,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To elucidate whether the presence of enhancing capsule can be applied to establish a modified Liver Imaging Reporting and Data System (LI-RADS) to differentiate hepatocellular carcinoma (HCC) from non-HCC malignancies in extracellular contrast agent (ECA)-enhanced and hepatobiliary agent (HBA)-enhanced MRI.

METHODS: We enrolled 198 participants (161 men; mean age, 56.3 years) with chronic liver disease who underwent ECA-MRI and HBA-MRI before surgery for de novo hepatic nodule(s). Two reviewers assigned LI-RADS categories (v2018). We defined a "modified LR-5 category, which emphasizes enhancing capsule (mLR-5C)" over targetoid features and classifies tumors with both targetoid appearance and enhancing capsule as HCC instead of LR-M. We compared the diagnostic performance of conventional LI-RADS and modified LI-RADS criteria for both MRIs.

RESULTS: A total of 258 hepatic nodules (194 HCCs, 43 benign lesions, and 21 non-HCC malignancies; median size, 19 mm) were analyzed. By conventional LI-RADS, 47 (18.2%) nodules (31 HCCs and 16 non-HCC malignancies) were categorized as LR-M. The mLR-5C criterion showed superior sensitivity (ECA-MRI, 76.6% vs. 67.0%; HBA-MRI, 60.4% vs. 56.3%; both p < 0.05) while maintaining high specificity (ECA-MRI, 93.8% vs. 98.4%; HBA-MRI, 95.3% vs. 98.4%; both p > 0.05) compared with the LR-5 criterion. Using the mLR-5C criterion, ECA-MRI exhibited higher sensitivity than HBA-MRI (76.6% vs. 60.4%, p < 0.001) and similar specificity (93.8% vs. 95.3%, p > 0.99).

CONCLUSION: Our modified LI-RADS achieved superior sensitivity for diagnosing HCC, without compromising specificity compared with LR-5. ECA-MRI showed higher sensitivity in diagnosing HCC than HBA-MRI by applying the mLR-5C for LR-M lesions.

KEY POINTS: • By conventional LI-RADS, 31 (16.0%) of 194 HCCs were categorized as LR-M. • Among 31 HCCs categorized as LR-M, 19 HCCs or 8 HCCs were recategorized as HCC on ECA-MRI or HBA-MRI, respectively, after applying the modified LR-5 category, which allocates targetoid lesions with enhancing capsule as mLR-5C instead of LR-M. • The mLR-5C showed superior sensitivity compared with the LR-5 in both MRIs (ECA-MRI, 76.6% vs. 67.0%; HBA-MRI, 60.4% vs. 56.3%, both p < 0.05), while maintaining high specificity (ECA-MRI, 93.8% vs. 98.4%; HBA-MRI, 95.3% vs. 98.4%; both p > 0.05).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Min JH, Kim JM, Kim YK, et al. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Eur Radiol. 2021. PMID: 34345947. doi:10.1007/s00330-021-08124-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。